Lexeo Therapeutics (LXEO) Other Non Operating Income (2023 - 2026)

Lexeo Therapeutics has reported Other Non Operating Income for 4 years, with the latest figure at -$1000.0 in Q1 2026.

• Quarterly Other Non Operating Income rose 75.0% year-over-year to -$1000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.5 million (down 912.96% YoY) and the FY2025 annual result came in at -$5.5 million, down 914.6% from the prior year.
• Other Non Operating Income rose to -$1000.0 in Q1 2026 per LXEO's latest filing, from -$5.5 million in the prior quarter.
• Over five years, Other Non Operating Income peaked at $687000.0 in Q4 2024 and troughed at -$5.5 million in Q4 2025.
• A 4-year average of -$373769.2 and a median of -$4000.0 in 2023 frame the typical range for Other Non Operating Income.
• The sharpest annual moves came in 2024 and 2025: Other Non Operating Income surged 9914.29% in 2024, then sank 1300.0% in 2025.
• Over 4 years, Other Non Operating Income stood at -$7000.0 in 2023, then soared by 9914.29% to $687000.0 in 2024, then plunged by 900.0% to -$5.5 million in 2025, then jumped by 99.98% to -$1000.0 in 2026.
• According to Business Quant data, Other Non Operating Income over the past three periods registered -$1000.0, -$5.5 million, and -$9000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.